课题基金 / 基金详情

Multi-group collaborative proposal: Diversity and function of prevalent uncharacterized exRNA species from tissue and biofluid

Multi-group collaborative proposal: Diversity and function of prevalent uncharacterized exRNA species from tissue and biofluid
多组合作提案:来自组织和生物体液的常见未表征 exRNA 种类的多样性和功能
批准号:
9452490
负责人:
Saumya Das
金额:
$7.78万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2019-07-31

项目摘要

项目成果

Saumya Das的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The complications of myocardial infarction contribute to 550,000 cases of heart failure (HF) and 300,000 cases of sudden cardiac arrest (SCA) annually. HF and SCA are mechanistically linked to the closely related processes of mechanical and electrical remodeling of the heart following infarction. Markers of adverse remodeling are widely used to risk-stratify post-MI patients for medical or device therapies. However, current risk-stratification strategies lack adequate sensitivity and specificity. Thus, development of complementary biomarkers to predict adverse outcomes post-MI is needed for the appropriate and cost-effective applications of these advanced therapies. Cellular micro-RNAs (miRNAs) regulate entire gene networks in human cardiovascular diseases and circulating miRNAs can be used as integrative biomarkers. We now propose to identify novel circulating miRNA signatures that can prognosticate susceptibility to arrhythmia/SCA and HF post-MI and to integrate these biomarkers into a digital PCR-based assay readily translatable into the clinic. Our group of investigators spanning multiple discipline within cardiovascular research will test the central hypothesis that (1) unbiased profiling of circulating plasma using RNA-seq will identify novel miRNAs associated with the development of adverse mechanical and electrical remodeling in a cohort of extensively-phenotyped post-MI patients; (2) mechanistic animal and cell culture models will complement the clinical discovery efforts by helping prioritize those markers that play a functional role in disease pathobiology, and (3) the assessment of miRNA signatures of adverse remodeling will enable accurate prediction of clinical outcomes, notably SCA and HF, in a large cohort of patients with CAD and MI. We believe that our results will lay the foundation for a novel strategy of risk-stratificationfor post-MI patients that would allow for identification of patients at high risk of adverse electrical and mechanical remodeling, who may benefit from more aggressive monitoring and interventions with medications and ICDs.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes.
胶原蛋白周转的生物标志物(C 端端肽)和非 ST 段抬高急性冠状动脉综合征患者的预后。
DOI: 10.1161/jaha.118.011444
发表时间: 2019
期刊: Journal of the American Heart Association
影响因子: 5.4
作者: [Zelniker,ThomasA, Jarolim,Petr, Scirica,BenjaminM, Braunwald,Eugene, Park,Jeong-Gun, Das,Saumya, Sabatine,MarcS, Morrow,DavidA]
通讯作者: Morrow,DavidA
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease
  • 批准号:
    10517890
  • 项目类别:
  • 资助金额:
    $82.0万
  • 财政年份:
    2022
  • 负责人:
    Saumya Das
  • 依托单位:
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk
  • 批准号:
    10706558
  • 项目类别:
  • 资助金额:
    $91.95万
  • 财政年份:
    2022
  • 负责人:
    Saumya Das
  • 依托单位:
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk
  • 批准号:
    10594228
  • 项目类别:
  • 资助金额:
    $95.84万
  • 财政年份:
    2022
  • 负责人:
    Saumya Das
  • 依托单位:
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease
  • 批准号:
    10706576
  • 项目类别:
  • 资助金额:
    $75.37万
  • 财政年份:
    2022
  • 负责人:
    Saumya Das
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: